This week, the newest pump coming to the market is called the twiist. It’s a very different shape – circular with a top half that twists off – with very different software – Tidepool Loop. The company behind this pump – they’re called Sequel – wants to be different as well, hoping to offer solutions to bigger issue than basal and bolus rates. It’s very ambitious and we have a wide ranging conversation about it all with Sequel’s CEO Alan Lotvin This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Our episode about Tidepool Loop approval
Episode summary:
New insulin pump technology with AI-based loop algorithm and discreet design.
- Dr. Alan Lotvin explains how the new insulin pump, Twist, directly measures insulin delivery and eliminates motors, gears, and syringes.
- Dr. Alan Lotvin highlights the small size and discreet design of the device, which holds three CCS and can be attached to the skin.
- The loop algorithm, developed by people with diabetes, offers flexibility and ease of use, with the ability to set glucose ranges and retrospectively adjust carb intake.
Insulin pump technology and its modern features.
- Dr. Alan Lotvin explains how the device measures insulin dosage using sound waves and a membrane.
- He describes the process of blowing a pulse of sound into a chamber, measuring the air column, and delivering insulin to the patient.
- Dr. Alan Lotvin explains how the pumping mechanism of the new insulin delivery device is different from traditional pumps.
- Dr. Alan Lotvin explains the features of a tube pump for insulin delivery, including discreet wear options.
- Stacey Simms highlights the creativity of the diabetes community in finding ways to wear insulin delivery devices.
New insulin pump with advanced features and compatibility with Dexcom CGM.
- Stacey Simms and Dr. Alan Lotvin discuss a new insulin pump design that is smaller and more discreet than traditional pumps.
- The pump has a circular shape and can be worn in various locations, including in a pocket or on the body, allowing for greater creativity and comfort.
- Dr. Alan Lotvin discusses the AI D system, a new insulin pump with a tighter loop algorithm that works with Dexcom CGM.
- The pump has a built-in bolus button and can operate without a phone nearby, providing more choices for users.
Diabetes management and new pump technology.
- The pump will alarm audibly for critical scenarios, which can be customized to some degree.
- DECA is working on a new pump with Lilly, similar to the Twist, but the story behind its development is unclear.
- Dr. Alan Lotvin speculates that Lily’s decision to focus on GLP-1s was driven by portfolio allocation, with the company seeing the ease of development and potential of GLP-1s in neuroscience and oncology.
- Dr. Lotvin suggests that DECA’s acquisition of the device from Lily was likely driven by the company’s desire to expand its portfolio and capitalize on the growing demand for GLP-1s.
- Dr. Alan Lotvin emphasizes the importance of making life better for people living with diabetes.
- He highlights the company’s commitment to choosing what’s right for patients over making a profit.
Insulin pumps and their compatibility with different insulin types and ages.
- Dr. Alan Lotvin discusses the insulin used by the pump and its stability and performance.
- Stacey Simms shares personal story of helping someone with diabetes access insulin, highlighting challenges faced by individuals without adequate healthcare.
Affordable insulin pricing and accessibility, with a focus on improving patient outcomes.
- Dr. Alan Lotvin discusses affordability of insulin therapy and new packaging options for insulin delivery.
- Dr. Alan Lotvin emphasizes the importance of making life easier for people living with diabetes.
- Dr. Alan Lotvin aims to create a small, high-capacity device with flexible algorithms to manage diabetes.
New insulin pump for type 1 and 2 diabetes, with focus on upcoming demos and clinical trials.
- Dr. Alan Lotvin plans to attend ADA conference and may attend other conferences.
- Dr. Alan Lotvin explains the company’s FDA-cleared loop algorithm and UI, and their plans for an IDE-controlled trial in type two diabetes.
- Dr. Lotvin discusses the off-label use of GLP ones for type one diabetes, and the challenges of retrospective carbohydrate changes.
AI-powered insulin pump for diabetes management.
- Dr. Alan Lotvin emphasizes the importance of personalized medicine in diabetes management, citing the need for flexible and adaptive algorithms that can learn and adjust to individual users’ needs.
- Dr. Lotvin is motivated by the desire to make a difference in people’s lives and to tackle the complex challenges of diabetes management through innovative technology.
- Dr. Alan Lotvin highlights the unique features of the AI D system, designed to improve clinical outcomes for people with type 1 diabetes.
- 63% of people living with type 1 diabetes are using an AI D system, indicating a need for innovation in the market.
- Dr. Alan Lotvin emphasizes the importance of patient-centric approach in developing the device, prioritizing ease of use and personalized support.
- He showcases the device’s compact design, with a small footprint of waste generated every three days.